ViroPharma Could Manufacture Cinryze "At Risk" Starting Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay in application for industrial scale production illustrates the challenges that biosimilar manufacturers will face.
You may also be interested in...
Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"
Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.
Dyax Kalbitor Is Third To Market For HAE, But First For All Acute Attacks
Overcoming an FDA advisory committee that expressed doubts about efficacy and potential hypersensitivity reactions and a "complete response" letter asking for a Risk Evaluation and Mitigation Strategy, Dyax won approval for Kalbitor (ecallantide) Nov. 27 to treat acute attacks of hereditary angioedema in patients 16 and older
FDA Won’t Require A Verification Study For Genzyme’s Lumizyme
Genzyme expects to resubmit its BLA, which received a complete response, by mid-May and have a six-month review.